Cynthia Pussinen reports a stock award at ESLA

By AlphaYouPublished Nov 4, 2026Form 4

Stocks in this disclosure

Reported activity

Pussinen Cynthia

Reporting filer

Cynthia Pussinen reports a stock award, not an open-market purchase or sale, in Estrella Immunopharma, Inc.. Form 4 filed Nov 4, 2026 lists 1 entry.

Reported details

1 entry

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Stock Option (Right to Buy) (derivative)	Pussinen Cynthia	2026-11-02	A	Grant or award	1000000	0	1,000,000	2 days	Filed terms security Title: Stock Option (Right to Buy) conversion Or Exercise Price: 0.43 transaction Date: 2026-11-02 transaction Form Type: 4 transaction Code: A equity Swap Involved: 0 id: F2 transaction Timeliness: transaction Shares: 1000000 transaction Price Per Share: 0 transaction Acquired Disposed Code: A id: F1 expiration Date: 2036-11-02 underlying Security Title: Common Stock underlying Security Shares: 1000000 shares Owned Following Transaction: 1000000 direct Or Indirect Ownership: D

Owner: Pussinen Cynthia
Date: 2026-11-02
Code: A
Action: Grant or award
Quantity: 1000000
Price: 0
Following holdings: 1,000,000
Reporting delay: 2 days
Filed terms and references: Filed terms
security Title: Stock Option (Right to Buy)
conversion Or Exercise Price: 0.43
transaction Date: 2026-11-02
transaction Form Type: 4
transaction Code: A
equity Swap Involved: 0
id: F2
transaction Timeliness:
transaction Shares: 1000000
transaction Price Per Share: 0
transaction Acquired Disposed Code: A
id: F1
expiration Date: 2036-11-02
underlying Security Title: Common Stock
underlying Security Shares: 1000000
shares Owned Following Transaction: 1000000
direct Or Indirect Ownership: D

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
Pussinen Cynthia: Chief Executive Officer, Director.
F1: The option vests and becomes exercisable as to 25% of the underlying shares on October 25, 2027 and as to the remaining 75% in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer through each vesting date.
F2: The option was granted under the Issuer's 2023 Omnibus Incentive Plan and was approved in advance by the Compensation Committee of the Board of Directors and the Board of Directors in accordance with Rule 16b-3(d).

Prepared automatically from public filing data. Report a correction.